Nationwide Functional Profiling Enables Clinical Reclassification of KCNH2 Variants in the French LQT2 Population

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: The increasing use of genetic testing has identified thousands of KCNH2 variants associated with long QT syndrome type 2 (LQT2), yet most remain variants of uncertain significance (VUS). Translating functional abnormalities into clinically actionable evidence remains a major challenge. We established a nationwide functional genomics strategy to systematically characterize KCNH2 variants identified in the French LQT2 population and improve their clinical interpretation. Methods: We characterized 303 KCNH2 variants, including 201 VUS, using standardized high-throughput automated patch-clamp electrophysiology and complementary membrane trafficking assays. Nine electrophysiological parameters were integrated using MeTAL to predict variant-specific repolarization phenotypes under homozygous and heterozygous conditions. Modeled QTc values were compared with patient electrocardiographic data and variant-specific penetrance estimates. Functional evidence was calibrated against established benign and pathogenic variants using ClinGen-recommended categorical OddsPath and continuous likelihood-ratio approaches. Results: Multidimensional functional profiling revealed abnormalities not captured by current amplitude alone, identifying additional variants with clinically relevant repolarization defects. Among variants assessed under heterozygous conditions, MeTAL predictions showed 82.9% concordance with patient QTc phenotypes for ACMG class 5 variants, with apparent discordances partly consistent with incomplete penetrance. Continuous likelihood-ratio calibration demonstrated strong discrimination between established benign and pathogenic variants (AUC=0.936) and provided graded functional evidence for 76.1% of VUS. Integration of calibrated functional evidence into the ACMG/AMP framework enabled reclassification of 64 of 201 VUS (31.8%), including 7 as pathogenic, 46 as likely pathogenic, and 11 as likely benign. Conclusions: This nationwide study establishes a scalable framework integrating high-throughput electrophysiology, computational modeling, and clinical phenotyping to translate complex KCNH2 channel dysfunction into clinically interpretable evidence. The resulting reclassification of nearly one-third of VUS, together with the open-access HAMMER database, provides a resource to improve molecular diagnosis and risk assessment in LQT2.

Article activity feed